The only legitimate way to get retatrutide at the moment is through a clinical trial
It should also not be used by people who have had bariatric surgery
Clinical trials have shown that dual agonists significantly reduce hepatic fat and NASH progression
GLP-1s are no longer just for type-2 diabetes along with weight management
Back Dupr, J, Ross, SA, Watson, D, Brown, JC (1973) 'Stimulation of insulin secretion by gastric inhibitory polypeptide in man', Journal Clinical Endocrinology Metabolism , 37, 826-8
But Retatrutides design carefully balances glucagon receptor activity in the presence of GLP-1 stimulation, and the net result is increased thermogenesis and energy expenditure rather than hyperglycemia